AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study
On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019 NEW YORK, Nov. 01, 2018...
Santhera Starting Phase 1b/2a Trial Testing Potential CF therapy POL6014
A Phase 1b/2a, dose-escalating clinical trial evaluating the effects of POL6014 in patients with cystic fibrosis (CF) was recently...
#WeCare and #MECFA advance CF care in the Middle East
“to improve and extend the lives of Cystic Fibrosis patients through disease awareness, advocacy and advanced care." MECFA The Middle...
#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators
Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco(ivacaftor) and tezacaftor (VX-661) can improve the lung function of...
PTI-808 and PTI-801 Combo Improves Lung Function in CF Patients, Phase 1 Data Show
Treatment with a combo of Proteostasis Therapeutics’ investigational CFTR modulator therapies — PTI-808, a potentiator, plus PTI-801, a...
#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Pha
Once-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by Celtaxsys, reduces the frequency...
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Pres
Pre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants Phase 2a results demonstrate RPL554 has favorable...
Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance
Boston-based Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801...
FDA Approves AzurRx Biopharma Request to Test MS1819-SD in CF Patients with EPI
AzurRx BioPharma is planning a multi-center Phase 2 trial to be conducted in the United States and Europe to evaluate its lead candidate...
Scientists Reveal New Cystic Fibrosis Treatments Work Best in Inflamed Airways
New UNC School of Medicine research led by Martina Gentzsch, PhD, and Carla Ribeiro, PhD, suggests that cystic fibrosis drugs used to...
